By leveraging the firm’s ultrasonic platform, the next-generation technology will enable topical and oral delivery of therapeutics to the gastrointestinal (GI) tract, including biologics and genetic medicines.
Suono Bio CEO Scott Kellogg said: “We are ecstatic to witness our foundational technology implemented in humans for the first time.
“This has been years in the making and puts us much closer to our goal of dramatically improving treatment options for serious gastrointestinal diseases and beyond.”
The SuonoCalm technology is being assessed for the topical administration of mesalamine to treat ulcerative colitis.
The safety and tolerability of the platform, including tissue-level drug concentrations, are being tested in the trial, which will help inform final treatment protocols.
Suono Bio co-founder and director professor Robert Langer said: “Since we first discovered the ability to deliver unformulated therapeutics, including RNA-based medicines, to the GI tract, the company has worked diligently to de-risk this technology and build out a meaningful pipeline of therapeutic candidates.
“The initiation of clinical testing begins a new phase for the company and helps serve to prove out not only the SuonoCalm, but the broader platform for enabling the oral delivery of biologics and other delicate medicines, the holy grail in drug delivery.”
Suono Bio is engaged in the development of new treatment solutions for the topical and oral delivery of biologics and genetic medicines in a formulation-independent manner.
The company’s platform was developed at The Massachusetts Institute of Technology in Robert Langer’s laboratory.